Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adil Daud

Showing results (51-60 of 103) with videos related to

Pageof 11
Sort By:
Journal of Clinical Pharmacology|December 31, 2013
The effects of a high-fat meal on single-dose vemurafenib pharmacokineticsAntoni Ribas, Weijiang Zhang, Ilsung Chang, et al.
BMC Medical Genomics|April 30, 2008
The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasisAdam I Riker, Steven A Enkemann, Oystein Fodstad, et al.
European Journal of Cancer (Oxford, England : 1990)|December 12, 2017
Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage IIIJean Jacques Grob, Dirk Schadendorf, Paul Lorigan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2006
Increased bioavailability of intravenous versus oral CI-1033, a pan erbB tyrosine kinase inhibitor: results of a phase I pharmacokinetic studyGeorge R Simon, Christopher R Garrett, Stephen C Olson, et al.
The Lancet. Oncology|July 20, 2014
Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b studyAntoni Ribas, Rene Gonzalez, Anna Pavlick, et al.
Molecular Therapy Oncolytics|May 20, 2022
Amplification of the CXCR3/CXCL9 axis via intratumoral electroporation of plasmid CXCL9 synergizes with plasmid IL-12 therapy to elicit robust anti-tumor immunityJack Y Lee, Bianca Nguyen, Anandaroop Mukhopadhyay, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 10, 2017
Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With TrametinibGeorgina V Long, Zeynep Eroglu, Jeffrey Infante, et al.
Cancer Cell|September 13, 2017
Dissecting the Tumor Myeloid Compartment Reveals Rare Activating Antigen-Presenting Cells Critical for T Cell ImmunityMiranda L Broz, Mikhail Binnewies, Bijan Boldajipour, et al.
Cancer Cell|December 3, 2014
Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunityMiranda L Broz, Mikhail Binnewies, Bijan Boldajipour, et al.
Scientific Reports|July 21, 2018
The lincRNA MIRAT binds to IQGAP1 and modulates the MAPK pathway in NRAS mutant melanomaMartina Sanlorenzo, Igor Vujic, Rosaura Esteve-Puig, et al.
Pageof 11

Showing results (51-60 of 103) with videos related to

Sort By:
Pageof 11
Journal of Clinical Pharmacology|December 31, 2013
The effects of a high-fat meal on single-dose vemurafenib pharmacokineticsAntoni Ribas, Weijiang Zhang, Ilsung Chang, et al.
BMC Medical Genomics|April 30, 2008
The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasisAdam I Riker, Steven A Enkemann, Oystein Fodstad, et al.
European Journal of Cancer (Oxford, England : 1990)|December 12, 2017
Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage IIIJean Jacques Grob, Dirk Schadendorf, Paul Lorigan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2006
Increased bioavailability of intravenous versus oral CI-1033, a pan erbB tyrosine kinase inhibitor: results of a phase I pharmacokinetic studyGeorge R Simon, Christopher R Garrett, Stephen C Olson, et al.
The Lancet. Oncology|July 20, 2014
Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b studyAntoni Ribas, Rene Gonzalez, Anna Pavlick, et al.
Molecular Therapy Oncolytics|May 20, 2022
Amplification of the CXCR3/CXCL9 axis via intratumoral electroporation of plasmid CXCL9 synergizes with plasmid IL-12 therapy to elicit robust anti-tumor immunityJack Y Lee, Bianca Nguyen, Anandaroop Mukhopadhyay, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 10, 2017
Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With TrametinibGeorgina V Long, Zeynep Eroglu, Jeffrey Infante, et al.
Cancer Cell|September 13, 2017
Dissecting the Tumor Myeloid Compartment Reveals Rare Activating Antigen-Presenting Cells Critical for T Cell ImmunityMiranda L Broz, Mikhail Binnewies, Bijan Boldajipour, et al.
Cancer Cell|December 3, 2014
Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunityMiranda L Broz, Mikhail Binnewies, Bijan Boldajipour, et al.
Scientific Reports|July 21, 2018
The lincRNA MIRAT binds to IQGAP1 and modulates the MAPK pathway in NRAS mutant melanomaMartina Sanlorenzo, Igor Vujic, Rosaura Esteve-Puig, et al.
Pageof 11